Join to View Full Profile
165 Cambridge StCPZ-7Boston, MA 02114
Dr. Dahl is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Douglas Dahl is a specialist in Urology and minimally Invasive Surgery and Surgical Oncology based in Boston, MA. He completed his medical education at the Yale School of Medicine in 1992 and then pursued his residencies in Surgery and Urology at Brigham and Women's Hospital/Harvard Medical School. His areas of expertise encompass prostate and bladder cancers, gynecologic and urologic oncology, and minimally invasive urologic surgery. Dr. Dahl actively participates in research, with several publications in reputed journals, and is involved in clinical trials focusing on bladder cancer treatments. He has been recognized as a Super Doctor by SuperDoctors.com and is a Fellow of the American College of Surgeons.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Harvard Medical SchoolResidency, Urology, 1994 - 1998- Mass General Brigham/Brigham and Women's HospitalResidency, Surgery, 1992 - 1994
Yale School of MedicineClass of 1992
Certifications & Licensure
MA State Medical License 1993 - 2026
ME State Medical License 2020 - 2026
RI State Medical License 2021 - 2026
NH State Medical License 2021 - 2025
American Board of Urology Urology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer Start of enrollment: 2005 Jul 26
Publications & Presentations
PubMed
- Single-cell and spatial transcriptomics reveal a tumor-associated macrophage subpopulation that mediates prostate cancer progression and metastasis.Shenglin Mei, Hanyu Zhang, Taghreed Hirz, Nathan Elias Jeffries, Yanxin Xu
Molecular Cancer Research. 2025-03-19 - 1 citationsBladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926.Douglas M Dahl, Joseph P Rodgers, William U Shipley, M Dror Michaelson, Chin-Lee Wu
Journal of Clinical Oncology. 2024-12-01 - 1 citationsUnsupervised Machine Learning to Identify Risk Factors of Pyeloplasty Failure in Ureteropelvic Junction Obstruction.Jonathan J Song, Jane Kielhofner, Zhiyu Jason Qian, Catherine Gu, William Boysen
Journal of Endourology. 2024-11-01
Press Mentions
Trimodal Therapy Promising for Recurrent High-Grade T1 Bladder CancerSeptember 12th, 2024- Higher PSA Screening Rates Tied to Lower Metastatic Prostate Cancer IncidenceOctober 28th, 2022
Ultrasound Therapy for Prostate Ca Yields High PSA ResponseMay 7th, 2019- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
